Shoshana Klein

Summary

Affiliation: The Hebrew University
Country: Israel

Publications

  1. doi Targeting the EGFR and the PKB pathway in cancer
    Shoshana Klein
    Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Givat Ram, Jerusalem, Israel
    Curr Opin Cell Biol 21:185-93. 2009
  2. doi Metabolic stability of peptidomimetics: N-methyl and aza heptapeptide analogs of a PKB/Akt inhibitor
    Yftah Tal-Gan
    Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    Chem Biol Drug Des 78:887-92. 2011
  3. doi Signal transduction therapy of cancer
    Alexander Levitzki
    Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Givat Ram, Jerusalem 91904, Israel
    Mol Aspects Med 31:287-329. 2010
  4. doi Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt)
    Yftah Tal-Gan
    Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    J Med Chem 54:5154-64. 2011
  5. doi Synthesis and structure-activity relationship studies of peptidomimetic PKB/Akt inhibitors: the significance of backbone interactions
    Yftah Tal-Gan
    Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    Bioorg Med Chem 18:2976-85. 2010
  6. ncbi Targeted cancer therapy: promise and reality
    Shoshana Klein
    Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel
    Adv Cancer Res 97:295-319. 2007
  7. doi Microwave-assisted solid-phase aza-peptide synthesis: aza scan of a PKB/Akt inhibitor using aza-arginine and aza-proline precursors
    Noam S Freeman
    Institute of Chemistry, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    J Org Chem 76:3078-85. 2011
  8. pmc Optimization of energy-consuming pathways towards rapid growth in HPV-transformed cells
    Sarit Mizrachy-Schwartz
    Unit of Cellular Signaling, Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel
    PLoS ONE 2:e628. 2007
  9. doi Studying protein-peptide interactions using benzophenone units: a case study of protein kinase B/Akt and its inhibitor PTR6154
    Yftah Tal-Gan
    Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    Anal Biochem 421:750-4. 2012
  10. ncbi Expression and purification of active PKB kinase from Escherichia coli
    Shoshana Klein
    Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Safra Campus, Jerusalem 91904, Israel
    Protein Expr Purif 41:162-9. 2005

Collaborators

Detail Information

Publications22

  1. doi Targeting the EGFR and the PKB pathway in cancer
    Shoshana Klein
    Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Givat Ram, Jerusalem, Israel
    Curr Opin Cell Biol 21:185-93. 2009
    ..Inhibition of the EGFR and PKB pathways also sensitizes cancer cells to chemotherapy. Thus, EGFR and PI3K/PKB inhibitors will be most effective when used in rational combinations of targeted inhibitors and traditional chemotherapy...
  2. doi Metabolic stability of peptidomimetics: N-methyl and aza heptapeptide analogs of a PKB/Akt inhibitor
    Yftah Tal-Gan
    Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    Chem Biol Drug Des 78:887-92. 2011
    ..Our results indicate that the modification site is important for metabolic stability and that aza-peptides have a more global effect than N-methylation, affecting cleavage sites distant from the modification site...
  3. doi Signal transduction therapy of cancer
    Alexander Levitzki
    Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Givat Ram, Jerusalem 91904, Israel
    Mol Aspects Med 31:287-329. 2010
    ....
  4. doi Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt)
    Yftah Tal-Gan
    Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    J Med Chem 54:5154-64. 2011
    ..Some activity trends could be rationalized using computational surface mapping of the PKB/Akt kinase catalytic domain. The novel molecules have enhanced pharmacological properties which make them promising lead candidates...
  5. doi Synthesis and structure-activity relationship studies of peptidomimetic PKB/Akt inhibitors: the significance of backbone interactions
    Yftah Tal-Gan
    Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    Bioorg Med Chem 18:2976-85. 2010
    ..Two N-terminal members of the N-methyl library did not decrease potency and can be used as future drug leads...
  6. ncbi Targeted cancer therapy: promise and reality
    Shoshana Klein
    Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel
    Adv Cancer Res 97:295-319. 2007
    ..We discuss the use of preclinical animal models to predict successful signal transduction therapy in the clinic, and conclude that their utility is limited...
  7. doi Microwave-assisted solid-phase aza-peptide synthesis: aza scan of a PKB/Akt inhibitor using aza-arginine and aza-proline precursors
    Noam S Freeman
    Institute of Chemistry, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    J Org Chem 76:3078-85. 2011
    ..This work will enable aza-scan to become a more common and standard method for structure-activity relationship studies of peptides...
  8. pmc Optimization of energy-consuming pathways towards rapid growth in HPV-transformed cells
    Sarit Mizrachy-Schwartz
    Unit of Cellular Signaling, Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel
    PLoS ONE 2:e628. 2007
    ..The cap to IRES-dependent switch seems to be part of a gradual optimization of energy-consuming mechanisms that redirects cellular processes to enhance cell growth, in the course of transformation...
  9. doi Studying protein-peptide interactions using benzophenone units: a case study of protein kinase B/Akt and its inhibitor PTR6154
    Yftah Tal-Gan
    Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    Anal Biochem 421:750-4. 2012
    ..As a proof of concept, we studied the interaction between protein kinase B (PKB/Akt) and its synthetic peptide inhibitor, PTR6154. The methodology is general and can be implemented to study PPIs in a variety of biological systems...
  10. ncbi Expression and purification of active PKB kinase from Escherichia coli
    Shoshana Klein
    Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Safra Campus, Jerusalem 91904, Israel
    Protein Expr Purif 41:162-9. 2005
    ..The final purification step, anion exchange over a monoQ column, separated phosphorylated from unphosphorylated protein. Active recombinant PKB kinase was thus produced from E. coli, by a simple, reproducible procedure...
  11. pmc Up-regulation of AMP-activated protein kinase in cancer cell lines is mediated through c-Src activation
    Sarit Mizrachy-Schwartz
    Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
    J Biol Chem 286:15268-77. 2011
    ..AMPK controls internal ribosome entry site (IRES) dependent translation in these cells. We suggest that AMPK activation via PKC might be a general mechanism to regulate IRES-dependent translation in cancer cells...
  12. ncbi Nucleic acid-based therapeutics for glioblastoma
    Alexei Shir
    Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Givat Ram, Jerusalem, Israel
    Anticancer Agents Med Chem 11:693-9. 2011
    ..Vectors applied in GBM for the delivery of nucleic acids will be discussed. These include non-replicating and replicating (oncolytic) viruses, as well as non-viral delivery vectors based on polycations or cationic lipids...
  13. doi Amino acid starvation sensitizes cancer cells to proteasome inhibition
    Sarit Mizrachy-Schwartz
    Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel
    IUBMB Life 62:757-63. 2010
    ..We hypothesize that protein catabolism contributes to the pool of free amino acids available for protein synthesis, leading to a crucial role of the proteasome in cell survival during amino acid depletion, in some tumor cell lines...
  14. ncbi Killing time for cancer cells
    Shoshana Klein
    Unit of Cellular Signalling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
    Nat Rev Cancer 5:573-80. 2005
    ..Can cancer be cured, or will it have to be controlled as a chronic disease?..
  15. ncbi The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest
    Hadas Reuveni
    Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel
    Eur J Biochem 270:2759-72. 2003
    ..The data suggest a new mechanism for FTI action, whereby in ras-transformed cells, the FTI causes an increase in p27Kip1 levels, which in turn inhibit cyclin E/Cdk2 activity, leading to G1 arrest...
  16. doi Contribution of gross chromosomal changes to HPV16-induced transformation
    Nataly Kravchenko-Balasha
    Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Safra Campus, Givat Ram, Jerusalem 91904, Israel
    Mol Biosyst 7:1501-11. 2011
    ..Our data are consistent with the theory that global chromosomal change is a necessary step in the process of cervical transformation...
  17. pmc Heterogeneity of gene expression in murine squamous cell carcinoma development-the same tumor by different means
    Noam Cohen
    Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel
    PLoS ONE 8:e57748. 2013
    ..The finding that gene expression is strongly heterogeneous in tumors that were induced by a standardized protocol in closely related mice underscores the need for molecular characterization of human tumors and personalized therapy...
  18. ncbi RNA molecules as anti-cancer agents
    Inbar Friedrich
    Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Givat Ram, Jerusalem 91904, Israel
    Semin Cancer Biol 14:223-30. 2004
    ..DKS has the potential to be applicable to a wide range of cancers. Thus dsRNA-based anti-cancer strategies could be powerful tools for cancer treatment...
  19. pmc Shift from apoptotic to necrotic cell death during human papillomavirus-induced transformation of keratinocytes
    Nataly Kravchenko-Balasha
    Unit of Cellular Signaling, Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Safra Campus, Givat Ram, Jerusalem 91904, Israel
    J Biol Chem 284:11717-27. 2009
    ..This study supports the hypothesis that the process of cancer transformation may be accompanied by a shift from apoptosis to necrosis...
  20. doi Novel method for the synthesis of urea backbone cyclic peptides using new Alloc-protected glycine building units
    Mattan Hurevich
    Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel
    J Pept Sci 16:178-85. 2010
    ..A set of urea backbone cyclic Glycogen Synthase Kinase 3 analogs was prepared and assessed for protein kinase B inhibition as anticancer leads...
  21. ncbi G-protein subunit dissociation is not an integral part of G-protein action
    Alexander Levitzki
    Unit of Cellular Signalling, Department of Biological Chemistry, The Alexander Silverman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
    Chembiochem 3:815-8. 2002
  22. ncbi Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design
    Hadas Reuveni
    Department of Biological Chemistry, The Silverman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel, and Peptor Ltd, Rehovot, Israel
    Biochemistry 41:10304-14. 2002
    ..We have identified structural features in NL-71-101 that are significant for the specificity and that can be used for future development and optimization of PKB inhibitors...